0.09
+0(+0.00%)
Currency In USD
Address
2200 Bridge Pkwy
Redwood City, DE 94065
United States of America
Phone
650 549 1400
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 10, 2020
Name | Title | Pay | Year Born |
Mr. Ronald A. Martell | President, Chief Executive Officer & Director | 1.04M | 1962 |
Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board & Director | 296,300 | 1957 |
Mr. Herbert C. Cross CPA | Chief Financial Officer & Corporate Secretary | 659,837 | 1972 |
Mr. Jeetinder Singh Mahal M.B.A. | Chief Operating Officer | 667,628 | 1973 |
Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer | 713,297 | 1972 |
Mr. Matthew Ford | Senior Vice President of Human Resources | 0 | N/A |
Ms. Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
Mr. David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy & Management | 0 | N/A |
Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research & Translational Medicine | 0 | N/A |
Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.